Status:
RECRUITING
Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
Lead Sponsor:
Shengjing Hospital
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18-60 years
Brief Summary
The incidence of breast cancer in Chinese women has increased year by year, and luminal A breast cancer commonly occurs in early-stage and postmenopausal women. This type of breast cancer is not sensi...
Detailed Description
Breast cancer ranks first in the incidence of female malignant tumors and second in mortality. It is mainly classified into luminal A, luminal B, human epidermal growth factor receptor 2 positive, bas...
Eligibility Criteria
Inclusion
- estrogen receptor (≥ 10%), progesterone receptor (≥ 10%) and epidermal growth factor receptor 2 negative;
- proliferation index Ki-67 \< 20%;
- no lymph node metastasis;
- systemic therapy (chemotherapy, radiotherapy and endocrine therapy) in accordance with the National Comprehensive Cancer Network guidelines;
- provision of informed consent of patients and their families.
Exclusion
- Bilateral breast cancer;
- inflammatory breast cancer;
- pregnancy or lactation;
- history of other cancers or chest radiotherapy.
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2029
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04065321
Start Date
October 1 2019
End Date
September 30 2029
Last Update
May 5 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
2
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China, 110042